You have 9 free searches left this month | for more free features.

Ibrutinib

Showing 1 - 25 of 368

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Cardiovascular Complications of Ibrutinib Therapy

Not yet recruiting
  • Ibrutinib Treatment
  • ophthalmological examination
  • blood test
  • Dijon, France
    Chu Dijon Bourgogne
Jul 3, 2023

Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Small Lymphocytic Lymphoma
  • (no location specified)
Jul 19, 2023

Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • (no location specified)
Aug 11, 2023

Mantle Cell Lymphoma Refractory Trial (Ibrutinib, Venetoclax, Navitoclax)

Not yet recruiting
  • Mantle Cell Lymphoma Refractory
  • Ibrutinib
  • +3 more
  • (no location specified)
May 16, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • (no location specified)
Nov 22, 2023

Glioblastoma Trial in Cleveland (Ibrutinib, Radiation, Temozolomide (TMZ))

Active, not recruiting
  • Glioblastoma
  • Ibrutinib
  • +2 more
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 30, 2023

Chronic Lymphocytic Leukemia Trial in Lebanon (BNC105P, Ibrutinib)

Completed
  • Chronic Lymphocytic Leukemia
  • BNC105P
  • Ibrutinib
  • Lebanon, New Hampshire
    Dartmouth-Hitchcock Medical Center
Jan 3, 2023

Chronic Lymphocytic Leukemia Trial (Evaluation of response to treatment with response-tailored Ibrutinib in patients with

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia
  • (no location specified)
Dec 27, 2022

Ependymoma, Medulloblastoma, Glioblastoma Trial in Augusta (Ibrutinib, Indoximod, Cyclophosphamide)

Recruiting
  • Ependymoma
  • +3 more
  • Ibrutinib
  • +3 more
  • Augusta, Georgia
    Augusta University, Georgia Cancer Center
Dec 16, 2022

Real World Data on Ibrutinib Use in PCNSL Rel/Ref

Recruiting
  • PCNSL
  • Ibrutinib
  • Milan, Italy
    Ospedale San Raffaele
Mar 13, 2023

Chronic GVHD Trial in Bethesda, Saint Louis (Ibrutinib)

Recruiting
  • Chronic GVHD
  • Ibrutinib
  • Bethesda, Maryland
  • +1 more
Jan 26, 2023

Malignant Tumors Stated as Primary Lymphoid Haematopoietic, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia Trial in

Active, not recruiting
  • Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
  • +2 more
  • Ibrutinib
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jan 20, 2023

Mantle Cell Lymphoma Trial in Houston (Ibrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Ibrutinib
  • Houston, Texas
    M D Anderson Cancer Center
Nov 1, 2022

Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Ibrutinib 420 mg)

Not yet recruiting
  • Autoimmune Hemolytic Anemia
  • +3 more
  • Ibrutinib 420 mg
  • (no location specified)
Jan 12, 2023

Waldenstrom's Macroglobulinemia Trial in Boston (Ibrutinib)

Completed
  • Waldenstrom's Macroglobulinemia
  • Ibrutinib
  • Boston, Massachusetts
  • +1 more
Dec 5, 2022

Unfit CLL Included in GIMEMA LLC1114 Trial Who Discontinued

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Observation
  • (no location specified)
Oct 12, 2023

CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Ibrutinib
  • Nivolumab
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Mantle Cell Lymphoma Recurrent Trial in Melbourne (ibrutinib and Tisagenlecleucel)

Active, not recruiting
  • Mantle Cell Lymphoma Recurrent
  • ibrutinib and Tisagenlecleucel
  • Melbourne, Victoria, Australia
    Peter Mac Callum Cancer Centre
Nov 4, 2022

Graft Vs Host Disease Trial in Atlanta (Rituximab, Ibrutinib)

Recruiting
  • Graft Vs Host Disease
  • Atlanta, Georgia
    Northside Hospital
Oct 19, 2022

T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma Trial in New York, Columbus (Ibrutinib)

Active, not recruiting
  • T-cell Lymphoma
  • Relapsed and Refractory T-cell Lymphoma
  • Ibrutinib
  • New York, New York
  • +1 more
Nov 8, 2022

Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),

Active, not recruiting
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Ibrutinib 560mg PO daily (Imbruvica)
  • +2 more
  • La Jolla, California
    UCSD Moores Cancer Center
Jan 11, 2023

Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022

Diffuse Large B-cell Lymphoma Trial in Tampa, Philadelphia (Tisagenlecleucel, Ibrutinib)

Terminated
  • Diffuse Large B-cell Lymphoma
  • Tisagenlecleucel
  • Ibrutinib
  • Tampa, Florida
  • +1 more
Jan 27, 2023

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +6 more
  • Ibrutinib
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 13, 2023

Diffuse Large B Cell Lymphoma Trial in Berlin (Ibrutinib and Bortezomib + R-CHOP)

Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • Ibrutinib and Bortezomib + R-CHOP
  • Berlin, Germany
    Charité - Universitätsmedizin Berlin, Hematology, Oncology and T
Aug 10, 2022